COMMUNIQUÉS West-GlobeNewswire

EDAP to Announce Third Quarter 2024 Financial Results on November 7, 2024

24/10/2024 - 14:00

Company to host conference call and webcast on Thursday, November 7 th at 8:30am EDT LYON, France, October 24, 2024 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, [...]

Prime Medicine Presents In Vivo Proof-of-Concept Data Highlighting Interim Preclinical Advances in its Wilson’s Disease Program and the Broad Potential of its Universal Liver-Targeted LNP at ESGCT 31st Annual Congress

24/10/2024 - 14:00

Delivery of Prime Editors with a proprietary, universal liver-targeted LNP was well tolerated, with no safety concerns or detectable off-target edits observed across multiple preclinical studies On track to initiate IND [...]

X4 Pharmaceuticals to Report Third-Quarter 2024 Financial and Phase 2 Chronic Neutropenia Study Results During Conference Call and Webcast on November 13, 2024

24/10/2024 - 14:00

BOSTON, Oct. 24, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that it will report financial [...]

Press Release: Dupixent late-breaking positive phase 3 data in chronic spontaneous urticaria to be presented at ACAAI

24/10/2024 - 14:00

Dupixent late-breaking positive phase 3 data in chronic spontaneous urticaria to be presented at ACAAI Dupixent significantly reduced itch and hive activity from baseline; 41% of patients achieved well-controlled [...]

Communiqué de presse : Dupixent : Présentation de nouvelles données positives de phase III dans le traitement de l’urticaire chronique spontanée au Congrès de l’ACAAI

24/10/2024 - 14:00

Dupixent : Présentation de nouvelles données positives de phase III dans le traitement de l’urticaire chronique spontanée au Congrès de l’ACAAI Le Dupixent a permis de réduire significativement le prurit et l’activité [...]

Bryn Pharma Appoints Joshua Ziel as Chief Executive Officer

24/10/2024 - 14:00

Seasoned Biotech Executive Further Strengthens Company’s Leadership Team Sandy Loreaux, former CEO, to Remain on Board of Directors LEBANON, N.J., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Bryn Pharma, LLC, a privately held [...]

Bayer and Dewpoint Therapeutics sign Licensing Agreement for Heart Disease Program

24/10/2024 - 14:00

Bayer obtains global license to develop and commercialize disease-modifying treatment specifically for dilated cardiomyopathy (DCM) patients characterized by specific mutations Post-licensing, companies will continue to [...]

Collegium to Report Third Quarter 2024 Financial Results on November 7, 2024

24/10/2024 - 14:00

STOUGHTON, Mass., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious [...]

Erasca Announces Strong Momentum for Naporafenib and RAS Targeting Franchise

24/10/2024 - 14:00

Positive preliminary Phase 1b SEACRAFT-1 data for naporafenib plus trametinib reinforce therapeutic potential in NRASm melanoma and further support ongoing Phase 3 SEACRAFT-2 trial SEACRAFT-2 has potential for approval [...]

Blue Cross and Blue Shield of Minnesota Foundation Awards More Than $4m to 18 Nonprofits

24/10/2024 - 14:00

EAGAN, Minn., Oct. 24, 2024 (GLOBE NEWSWIRE) -- The Blue Cross and Blue Shield of Minnesota Foundation has awarded $4.08M in grants to 18 nonprofit organizations in Minnesota, as part of its focus on increasing [...]

Provectus Biopharmaceuticals Announces Investor Webinar for Fourth Quarter 2024 Conference Call

24/10/2024 - 14:00

KNOXVILLE, Tenn., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) announced today that its Fourth Quarter 2024 Investor Update will be accessible by Zoom [...]

PeopleOne Health Secures up to $32.3 Million Series B Funding Led by GV (Google Ventures) to Expand Access to Affordable, High-Quality Primary Care

24/10/2024 - 13:30

New funding will support strategic expansion of PeopleOne Health, improving access to preventive care and treatment to keep people healthier throughout communities in the U.S. PITTSBURGH, Oct. 24, 2024 (GLOBE NEWSWIRE [...]

Kura Oncology Reports Preclinical Data Supporting Opportunity for Ziftomenib in Treatment of Gastrointestinal Stromal Tumors (GIST)

24/10/2024 - 13:30

– Combination of ziftomenib and imatinib shows robust and durable antitumor activity in imatinib-sensitive (1L) and imatinib-resistant (2L/3L) GIST models – – Proof-of-concept study of ziftomenib plus imatinib in [...]

Soligenix, Inc. to Present at the 2024 ThinkEquity Conference

24/10/2024 - 13:30

PRINCETON, N.J., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Soligenix, Inc. (Nasdaq: SNGX) (“Soligenix” or the “Company”) a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare [...]

BridgeBio Shares Positive Data from High Dose Cohort of Phase 1/2 CANaspire Study of Gene Therapy BBP-812 for Canavan Disease at ESGCT 2024

24/10/2024 - 13:30

- Continued, progressive improvement in motor function and achievement of motor milestones at 12-months post-treatment represents an important and statistically significant change, in contrast to the disease course [...]

Biogen to Present New Data at the Clinical Trials on Alzheimer's Disease (CTAD) 2024 Annual Conference

24/10/2024 - 13:30

CAMBRIDGE, Mass., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced upcoming data presentations and programming at the Clinical Trials on Alzheimer’s Disease (CTAD) annual conference, taking place [...]

Prelude Therapeutics Presents New Data from SMARCA Degrader Portfolio at the 36th EORTC-NCI-AACR Symposium

24/10/2024 - 13:30

– Interim data from ongoing trial of PRT3789 showed additional clinical activity at higher doses in patients with non-small cell lung cancer (NSCLC) – First safety data presented from combination study of PRT3789 and [...]

The Joint Corp. to Host Conference Call on Thursday, November 7th to Discuss Third Quarter 2024 Results

24/10/2024 - 13:05

SCOTTSDALE, Ariz., Oct. 24, 2024 (GLOBE NEWSWIRE) -- The Joint Corp. (NASDAQ: JYNT) the nation's largest franchisor of chiropractic care through The Joint Chiropractic® network, announced it will report its third [...]

Verrica Pharmaceuticals Announces Acceptance of Two Abstracts Featuring Positive Preliminary Topline Results of VP-315 for the Treatment of Basal Cell Carcinoma at the 2024 Fall Clinical Dermatology Conference

24/10/2024 - 13:00

- Posters to highlight the safety data, tolerability data, and antitumor efficacy data of VP-315 for the treatment of basal cell carcinoma as determined by histological clearance - WEST CHESTER, Pa., Oct. 24, 2024 ( [...]